ECErik Cimé-Aké

Erik Cimé-Aké

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erik Cimé-Aké has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Remission, low disease activity and relapse in patients with juvenile-, adult- and late-onset SLE

    by Adriana Elizabeth Vázquez Hernández, Emilio Godínez-Lazarini, Erik Cimé-Aké, Hilda Fragoso-Loyo

    Objective: To evaluate remission, low disease activity and relapse in patients with SLE according to age at disease onset. Methods: We conducted a retrospective cohort study including patients classified with SLE according to the 2019 EULAR/ACR criteria. Patients were grouped by age at onset as juvenile-onset SLE (jSLE, <18 years), adult-onset SLE (aSLE, 18–49 years) and late-onset SLE (lSLE, ≥50 years). Patients with other autoimmune diseases were excluded, except antiphospholipid syndrome and Sjögren. Clinical data and outcomes were obtained from medical records. Remission was defined according to DORIS, low disease activity according to LLDAS and relapse according to the SELENA-SLEDAI Flare Index. Results: A total of 289 patients were included: 96 with jSLE, 96 with aSLE and 97 with lSLE; 90.5% female. At diagnosis, jSLE patients had higher disease activity. Neuropsychiatric manifestations were more frequent in jSLE, while mucocutaneous involvement and nephritis predominated in aSLE. Remission and LLDAS were achieved more frequently in lSLE; concordantly, lSLE independently predicted remission and LLDAS (HR 2.8; 95% CI 1.9–4.0 and HR 2.4; 95% CI 1.7–3.4; P < 0.001). Relapses were more frequent in jSLE (87.5%) compared with aSLE (66.7%) and lSLE (24.7%; P < 0.001). Factors associated with relapse were jSLE (HR 2.1; 95% CI 1.5–2.9; P = 0.008) and constitutional manifestations at onset (HR 1.6; 95% CI 1.2–2.4; P = 0.048). Mortality was higher in lSLE, with infections as the main cause. Conclusion: jSLE was associated with higher relapse rates, whereas late-onset SLE was independently associated with achieving remission and LLDAS.

  • Open Access

    Self-esteem as a determinant of sexual function in systemic lupus erythematosus patients: a cross-sectional study

    by Daniela Marengo-Rodríguez, María Espinosa-León, Monserrat Ibarra-Velasco-Siles, Paola Vázquez-Cárdenas, Erik Cimé-Aké, Jonathan Campos-Guzmán, Ana Barrera-Vargas, Javier Merayo-Chalico

    Background: The correlation between self-esteem and sexual function in systemic lupus erythematosus (SLE) patients remains unexplored. The objective was to assess the association between body self-esteem, global self-esteem, and sexual function in patients with SLE. Methods: A cross-sectional study was conducted at a tertiary care center. We included patients aged 18 and older who met the EULAR/ACR criteria for SLE. Body self-esteem was measured using the Body Self-Esteem Scale (BSES), while global self-esteem was assessed with the Rosenberg Self-Esteem Scale (RSE). Sexual function was evaluated using the Changes in Sexual Functioning Questionnaire Short-Form questionnaire (CSFQ-14). Sexual dysfunction (SD) was defined as a total CSFQ-14 score of less than 41 points for women and less than 47 points for men. We assessed disease activity using the SLEDAI-2 K, and damage accrual with the SLICC damage index. Results: A total of 280 patients were included, the majority of whom were female (88.6%). The median age was 39 years (IQR 31 to 49). The median SLEDAI-2 K score was 2 (IQR 0 to 4), and the SLICC damage index was 0 (IQR 0 to 1). A total of 147 patients (52.5%) were classified as having SD. The BSES score showed a significant correlation with the total CSFQ-14 score (rho = 0.364, p < 0.001). Similarly, the RSE subcomponents, self-competence (rho = 0.262, p < 0.001) and self-liking (rho = 0.274, p < 0.001) showed both a significant positive correlation with the total CSFQ-14 score. Patients with SD compared to those without SD had significantly lower BSES scores, lower self-competence scores and lower self-liking scores. Female sex (OR 2.6, 95% CI 1.2 to 6.0, p = 0.026), lower leukocyte count (OR 1.2, 95% CI 1.0 to 1.3, p = 0.046), and lower BSES score (OR 1.9, 95% CI 1.8 to 2.1, p < 0.001) were independent risk factors for sexual dysfunction. Conclusions: This is the first study to evaluate self-esteem as a determinant of sexual function in SLE patients. Given the significant impact of self-esteem on sexual dysfunction, its relationship should be assessed during rheumatology evaluations. Clinical trial number: Not applicable.

  • Subcutaneous Sweet Syndrome as an uncommon mucocutaneous manifestation in systemic lupus erythematosus: a case report and literature review

    by Erik Cimé-Aké, David Arriaga Escamilla, Javier Ríos-Valencia, Marcela Saeb-Lima, Hilda Fragoso-Loyo

  • Association of the 2022 ACR/EULAR Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis With Disease Activity and Damage Accrual: A Retrospective Cohort Study

    by Erik Cimé-Aké, Eduardo Rojas-Milán, Gabriela Medina, María del Pilar Cruz-Domínguez, Olga Vera-Lastra

    Objective: To explore whether the 2022 ACR/EULAR Classification Criteria (2022 AECC) for eosinophilic granulomatosis with polyangiitis (EGPA) are associated with disease activity at diagnosis and damage accrual during follow-up in a real-world cohort. Methods: We conducted a retrospective cohort study including patients with a clinical diagnosis of EGPA and at least one year of follow-up. The 2022 AECC score was calculated at the time of diagnosis. Disease activity at baseline was assessed with the Birmingham Vasculitis Activity Score (BVAS), and damage at the last visit with the Vasculitis Damage Index (VDI); severe damage was defined as VDI ≥3. The performance of the AECC score for identifying patients with severe damage was examined descriptively. Results: Thirty patients were included. Their clinical features were broadly comparable to those described in previous EGPA cohorts. According to the 2022 AECC, 90% of patients met classification criteria, and 80% had severe damage. Higher AECC scores were more frequently observed in patients with obstructive airway disease, marked eosinophilia, and P-ANCA/anti-MPO positivity. The AECC score showed a positive correlation with BVAS at diagnosis (ρ=0.756, p p <0.001). The cutoff of 8 points appeared to discriminate against patients with severe damage. Conclusion: In this exploratory study, higher 2022 AECC scores at diagnosis were associated with greater disease activity and damage accrual. These findings should be interpreted as exploratory observations. A prospective evaluation of the clinical implications of classification scores beyond their intended purpose is needed.

  • Pancarditis and fibrosis as hallmarks of lupus myocarditis: clinical features, imaging findings and outcomes

    by María del Carmen Zamora-Medina, Erik Cimé-Aké, Emilio Godínez-Lazarini, Wallace Rafael A Muñoz-Castañeda, Griselda Medina-Montaño, Hilda Fragoso-Loyo

    Objectives: To describe and compare the clinical features, imaging findings and outcomes of lupus myocarditis (LM) patients with those of active systemic lupus erythematosus (SLE) without myocarditis (SLE–non-LM) and acute myocarditis non-autoimmune (AM–non-AI) patients. Methods: This was a retrospective cohort study including 32 LM patients diagnosed between 2005 and 2022, matched 1:1 by age and sex with active SLE–non-LM and AM–non-AI groups. SLE patients (EULAR/ACR 2019) had clinically suspected myocarditis by European Society of Cardiology criteria, confirmed by cardiac magnetic resonance (CMR) imaging (Updated Lake Louise criteria). Clinical, laboratory, electrocardiographic, echocardiographic and CMR findings, as well as outcomes, were compared across groups with a 2-year follow-up. Results: LM patients presented with higher rates of fever and cardiogenic shock compared with AM–non-AI. Echocardiography revealed significantly more wall motion abnormalities (71.9% vs 25.0%, P < 0.001), reduced left ventricular ejection fraction (56.3% vs 18.8%, P = 0.002), pulmonary hypertension (37.5% vs 3.1%, P = 0.001) and valvular abnormalities (65.5% vs 3.1%, P < 0.001). On CMR, LM patients had a higher prevalence of late gadolinium enhancement (65.6% vs 37.5%, P = 0.024) and higher rates of pericardial involvement and valvular regurgitation. Pancarditis was identified exclusively in LM patients (65.6% vs 0%, P < 0.001). Outcomes were worse in LM, with increased ICU admission (28.1% vs 6.3%, P = 0.043) and invasive mechanical ventilation (25.0% vs 3.1%, P = 0.027). However, 2-year mortality was comparable between LM and AM–non-AI groups. Conclusion: LM is a distinct and severe phenotype of SLE, characterized by pancarditis and unique imaging features. Echocardiography and CMR are pivotal in early recognition, with prognostic implications.


  • Dysautonomia as a form of presentation of primary Sjögren’s disease: a case series of six patients

    by Emilio Godínez-Lazarini, Erik Cimé-Aké, Mitzi Peña-Ojeda, Javier Ríos-Valencia, David Faz-Muñoz, Gabriela Hernández-Molina, Hilda Fragoso-Loyo

    We present six patients with dysautonomia secondary to primary Sjögren’s disease (pSjD) and analyze the literature regarding this topic. Case series. Patients were retrospectively recruited from a tertiary center in Mexico from 2001 to 2022 and included if they met 2016 ACR/EULAR criteria for SjD. Dysautonomia was diagnosed by the presence of autonomic symptoms and at least one of Ewin’s battery tests. We scored the Composite Autonomic Severity Scale (CASS), and the Composite Autonomic Symptom Score (COMPASS-31). Patients (n = 6) were primarily females (83%), with a range of 23 to 60 years at onset of neurological manifestations. Dysautonomia preceded 2–10 years the diagnosis of pSjD in five patients. The clinical manifestations varied, but all patients had orthostatic hypotension and syncope. Patients had variability regarding non-neurological disease activity (ESSDAI 0–15) at the onset of neurological manifestations. Treatment for dysautonomia included prednisone, hydroxychloroquine, DMARDs, rituximab, or their combinations. Overall, we observed partial improvement in most of the cases and only one patient had remission of her symptoms of dysautonomia. Two patients discontinued treatment and lost follow-up. Few cases of dysautonomia and biopsy proven pSjD were identified in the literature, but they shared clinical features with ours. Dysautonomia is a rare and challenging neurological manifestation attributed with pSjD. The main symptoms in our patients were orthostatic hypotension and syncope; and most of the times preceded SjD diagnosis. Partial improvement was achieved in the majority of patients following treatment.


  • Severe systemic inflammatory response and acute kidney injury induced by Kambô intoxication

    by Erick Daniel Alvarez-Boizo, Diana Ugalde-Soto, Jesús Pinedo-Vázquez, Gabriel Zavala-Rodríguez, Gibran Felipe Azamar-Morales, Zeltzin Olivia Guerrero-Mancinas, Manuel Alejandro Marroquin-Barrera, Erik Cimé-Aké


  • HALP Score for Predicting Renal Relapse in Lupus Nephritis

    by Jeny A. Marín-Corte, Alfredo Atl Castillo-Sigales, Hilda Msc Fragoso-Loyo, Erik Cimé-Aké

    Objective: To evaluate the HALP (hemoglobin-albumin-lymphocyte-platelet) score at lupus nephritis (LN) diagnosis in predicting renal relapse (RR). Methods: Nested case-control study, including patients aged ≥18 years with diagnosis of LN between 2010 and 2022. Two patient sets were included: training and validation. Each set had 2 groups of patients: RR and non-RR. Data were obtained from clinical records. The optimal cutoff value of the HALP score at LN diagnosis was established to predict RR. Cox regression analysis was used to associate HALP score at diagnosis with RR. Results: We included 53 LN patients in the training set and 74 LN patients in the validation set. The optimal cutoff value for HALP score at diagnosis was 23.5, with an area under the curve of 0.896, sensitivity of 91.9%, and specificity of 97.3% in the validation set. The median age of patients in this set was 31.0 years, mostly female (93%). In the validation set, LN patients with HALP score at diagnosis ≤23.5 compared with higher HALP score subjects showed a significantly higher baseline SLEDAI-2K (18 [interquartile range {IQR}, 14–20] vs. 14 [IQR, 11–17], p < 0.001), Systemic Lupus Collaborating Clinics/American College of Rheumatology Damage Index at the end of the follow-up (1 [IQR, 0–4] vs. 0 [IQR, 0–1], p = 0.002), chronicity index in renal biopsy (2 [IQR, 1–4] vs. 1 [IQR, 1–2], p = 0.030), and significantly reduced time to RR (4.2 vs. 12.9 years, p < 0.001). A HALP score at diagnosis ≤23.5 was associated with RR (hazard ratio, 18.2; 95% confidence interval, 5.3–30.1; p < 0.001). Conclusion: A HALP score ≤23.5 at LN diagnosis was an independent risk factor for RR.


  • Performance of the 2023 American College of Rheumatology/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort

    by Erik Cimé‐Aké, Gabriela Hernández‐Molina, Amaya Llorente‐Chávez, Eduardo Martín‐Nares

    Objective: The objective is to assess the performance of the 2023 American College of Rheumatology/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) in a Mexican cohort.Methods: We enrolled patients with primary APS (PAPS) and secondary APS (SAPS) and a control group of nonautoimmune thrombophilia. We evaluated the fulfillment of the 2023 AECC and the 2006 revised Sapporo classification criteria (2006 RSCC) and their performance against the clinical diagnosis as the gold standard. The baseline Global APS Score (GAPSS) and the Damage Index for APS (DIAPS) at last follow‐up were calculated.Results: We included 85 patients with PAPS, 54 with SAPS, and 50 with thrombophilia. According to the 2023 AECC criteria, 69 patients (81.2%) with PAPS, 28 patients (51.9%) with SAPS, and none of the patients with thrombophilia met the criteria. When comparing true positive (TP) (n = 69) versus false negative (n = 16) cases within the PAPS group, TP cases exhibited a higher frequency of thrombotic manifestations and IgM anti‐cardiolipin and IgG anti–β2‐glycoprotein‐I positivity. For PAPS, there was a correlation between the 2023 AECC score and both GAPSS (rho = 0.621, P < 0.0001) and DIAPS scores (rho = 0.433, P < 0.0001). When comparing the 2023 AECC with the 2006 RSCC, a lower sensitivity (81.2% vs 88.2%) but a higher specificity (100.0% vs 92.0%) was observed for PAPS. Similar findings were observed in SAPS.Conclusion: In both PAPS and SAPS, the 2023 AECC have higher specificity than the 2006 RSCC. The main feature of patients with PAPS according to the 2023 AECC was thrombosis. These criteria might identify patients at higher risk of thrombosis and damage accrual. image


  • Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse

    by Erik Cimé-Aké, Ana Barrera-Vargas, Roberta Demichelis-Gómez, Martha Ramírez-Alemón, Marina Rull-Gabayet

    Objectives To describe the response and relapse of severe thrombocytopenia in patients with systemic lupus erythematosus (SLE) with different treatments. Method We performed a retrospective cohort study, which included SLE patients who were hospitalized for thrombocytopenia of less than 30,000/µL platelets, from January 2012 to December 2021. Demographic and clinical information was obtained from clinical records. Kaplan–Meier and logrank test were performed. Results Forty-seven patients, mostly women (83%) with a median age of 31 years, were included in the study. Eight patients (17%) relapsed within a median period of 35.7 weeks. Initial acute treatment with prednisone at 1 mg/kg/day was as effective as glucocorticoid pulses. However, induction treatment with cyclophosphamide (CYC) had the lowest remission rate (43%, p = 0.034). There was no significant difference in relapse-free survival (RFS) among the acute glucocorticoid treatments. CYC induction was associated with lower RFS compared to rituximab (RTX) (CYC 43.6 weeks vs. RTX 51.8 weeks, p = 0.040) or azathioprine (AZA) (CYC 43.6 weeks vs. AZA 51.2 weeks, p = 0.024). Administration of antimalarials was associated with longer RFS (51.6 weeks vs. 45.0 weeks, p = 0.021). Factors such as antiphospholipid syndrome, IgG anti-β2 glycoprotein I positivity, renal and additional hematologic SLE activity during follow-up significantly reduced RFS. Conclusions Despite similar response of acute glucocorticoid regimens, induction therapy with AZA or RTX resulted in a longer RFS compared to CYC. Adding an antimalarial also improved RFS. Our study provides evidence that may help develop better treatment strategies for severe thrombocytopenia in SLE patients. Key Points • Induction therapy with azathioprine or rituximab provided longer relapse-free survival in SLE thrombocytopenia compared with cyclophosphamide. • Antimalarial administration was associated with longer relapse-free survival in SLE thrombocytopenia. • Antiphospholipid syndrome, IgG anti-β2 glycoprotein I positivity, as well as renal and additional hematologic SLE activity during follow-up, decreased relapse-free survival.